← Back to Search

Tyrosine Kinase Inhibitor

Afatinib + Pemigatinib for Solid Tumors

Phase 1
Recruiting
Led By Andreas Varkaris, MD
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, every 9 weeks during treatment and off study up to 1 year
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing if a combination of two drugs, Afatinib and Pemigatinib, is safe and effective for treating certain types of advanced solid tumors with specific genetic mutations. The study

Who is the study for?
This trial is for individuals with advanced solid tumors that can't be removed by surgery or have spread (metastatic), and whose tumors have specific genetic alterations called FGFR. The exact eligibility criteria are not provided, but typically participants must meet certain health standards to ensure safety.
What is being tested?
The study is testing the combination of two drugs, Afatinib and Pemigatinib, to see if they're safe and effective against advanced solid tumors with FGFR alterations. It also aims to find the highest doses patients can take without severe side effects.
What are the potential side effects?
While specific side effects aren't listed here, common ones for cancer treatments like Afatinib and Pemigatinib may include diarrhea, skin issues, mouth sores, loss of appetite, fatigue, nail changes, and potential liver problems.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, every 9 weeks during treatment and off study up to 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, every 9 weeks during treatment and off study up to 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Maximum tolerated dose (MTD)
Objective response rate (ORR)
Secondary study objectives
Best Overall Response
Disease Control Rate
Duration of Response
+6 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: DOSE ESCALATION PHASE 1A PEMIGATINIB + AFATINIBExperimental Treatment2 Interventions
In the phase 1a dose escalation study participants with FGFR-altered refractory advanced solid tumors will be enrolled. This research study involves the study drugs Afatinib and Pemigatinib.
Group II: COHORT 2: EXPANSION PHASE 1B COHORT 2 MTD/RP2D PEMIGATINIB + AFATINIB FGFR INHIBITOR-PRETREATEDExperimental Treatment2 Interventions
In the phase Ib dose expansion study, patients with FGFR-altered cholangiocarcinoma will be recruited into 2 cohorts: FGFR inhibitor-naïve cholangiocarcinoma and FGFR-inhibitor-pretreated and resistant cholangiocarcinoma. Cohort 2 will enroll patients with FGFR-inhibitor-pretreated and resistant cholangiocarcinoma. This research study involves the study drugs Afatinib and Pemigatinib.
Group III: COHORT 1: EXPANSION PHASE 1B COHORT 1 MTD/RP2D PEMIGATINIB + AFATINIB FGFR INHIBITOR-NAIVEExperimental Treatment2 Interventions
In the phase Ib dose expansion study, patients with FGFR-altered cholangiocarcinoma will be recruited into 2 cohorts: FGFR inhibitor-naïve cholangiocarcinoma and FGFR-inhibitor-pretreated and resistant cholangiocarcinoma. Cohort 1 will enroll patients with FGFR inhibitor-naïve cholangiocarcinoma. This research study involves the study drugs Afatinib and Pemigatinib.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pemigatinib
2022
Completed Phase 2
~250
Afatinib
2016
Completed Phase 4
~2340

Find a Location

Who is running the clinical trial?

Boehringer IngelheimIndustry Sponsor
2,548 Previous Clinical Trials
11,387,661 Total Patients Enrolled
1 Trials studying Cholangiocarcinoma
110 Patients Enrolled for Cholangiocarcinoma
Incyte CorporationIndustry Sponsor
389 Previous Clinical Trials
63,685 Total Patients Enrolled
5 Trials studying Cholangiocarcinoma
565 Patients Enrolled for Cholangiocarcinoma
Massachusetts General HospitalLead Sponsor
3,005 Previous Clinical Trials
13,309,720 Total Patients Enrolled
7 Trials studying Cholangiocarcinoma
153 Patients Enrolled for Cholangiocarcinoma
~14 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top